Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
109.5 USD | +1.89% | -0.44% | -11.01% |
Sales 2024 * | 4.09B 328B | Sales 2025 * | 4.39B 351B | Capitalization | 6.82B 546B |
---|---|---|---|---|---|
Net income 2024 * | 475M 38.02B | Net income 2025 * | 648M 51.87B | EV / Sales 2024 * | 2.46 x |
Net Debt 2024 * | 3.27B 262B | Net Debt 2025 * | 1.79B 143B | EV / Sales 2025 * | 1.96 x |
P/E ratio 2024 * |
16.5
x | P/E ratio 2025 * |
11.2
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.18% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | +1.89% | ||
1 week | -0.44% | ||
Current month | -9.10% | ||
1 month | -7.18% | ||
3 months | -10.67% | ||
6 months | -15.07% | ||
Current year | -11.01% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 28/02/03 |
Renée Galá
PSD | President | 52 | 15/03/20 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 28/05/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 28/02/03 |
Norbert Riedel
BRD | Director/Board Member | 66 | 12/05/13 |
Patrick Enright
BRD | Director/Board Member | 62 | 31/12/08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 13 M€ | -.--% | ||
14.47% | 215 M€ | +10.68% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 109.5 | +1.89% | 480,575 |
25/04/24 | 107.4 | -0.82% | 424,856 |
24/04/24 | 108.3 | -1.23% | 401,342 |
23/04/24 | 109.7 | +0.77% | 376,841 |
22/04/24 | 108.8 | -1.01% | 514,011 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.01% | 6.82B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- JAZZ Stock